← SEC 公告列表 | BBIO SEC 公告 | BridgeBio Pharma, Inc.（BBIO）

季報 季度報告 10-Q 2026-08-10

BridgeBio Pharma第二季收入倍增達2.4億美元 三項後期管線步入審評

於 SEC 網站開啟原文

AI 繁中摘要

BridgeBio Pharma（納斯達克：BBIO）公佈截至2026年6月30日止第二季度及上半年業績（10-Q表格）。受核心產品Attruby（acoramidis）持續放量帶動，公司季度總收入達2.436億美元，按年大增逾一倍；上半年累計收入4.382億美元，同樣遠超去年同期的2.272億美元。 業績重點方面，第二季產品淨收入為2.224億美元（上半年4.030億美元），是收入增長的主要引擎；許可及服務收入580萬美元，特許權使用費收入1,540萬美元。公司仍處於虧損狀態，第二季淨虧損1.559億美元，每股虧損0.78美元；上半年累計淨虧損3.224億美元，每股虧損1.62美元，虧損幅度均較去年同期有所收窄。 產品管線方面，研發進展密集： - BBP-418（治療肢帶型肌肉萎縮症2I/R9型）已向FDA提交新藥申請（NDA），獲優先審評，PDUFA目標日期為2026年11月27日； - encaleret（治療自體顯性低鈣血症1型）NDA已獲接納，PDUFA目標日期為2027年5月8日； - 低劑量infigratinib（治療軟骨發育不全症）亦已提交NDA。 財務狀況方面，截至2026年6月30日，公司持有現金及現金等價物6.779億美元，加上有價證券後流動資金充裕。期內完成發行2033年到期可換股高級票據，集資淨額約6.19億美元，並動用2.1億美元回購股份，反映管理層對業務前景的信心。現金流方面，上半年經營業務現金流出2.684億美元。 後續事項方面，公司於7月簽訂投資協議，發行A系列累計可換股參與優先股，涉及Sixth Street及HCR等投資者，預計進一步強化資產負債表。 對投資者而言，Attruby的商業化進展理想，加上三項後期管線候選藥物均步入監理審評階段，是股價的潛在催化劑；惟公司仍處虧損階段，需持續留意銷售增長能否支持估值。
展開英文正文 
bbio-202606300001743881202612/31Q2FALSE0.02007730.0103050.02341510.00904350.25443xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesbbio:product_candidatexbrli:purebbio:customerbbio:segmentbbio:trading_daybbio:performance_obligationbbio:quarter00017438812026-01-012026-06-3000017438812026-08-0300017438812026-06-3000017438812025-12-310001743881bbio:A2027ConvertibleSeniorNotesMember2026-06-300001743881bbio:A2027ConvertibleSeniorNotesMember2025-12-310001743881bbio:A2029ConvertibleSeniorNotesMember2026-06-300001743881bbio:A2029ConvertibleSeniorNotesMember2025-12-310001743881bbio:A2031ConvertibleSeniorNotesMember2026-06-300001743881bbio:A2031ConvertibleSeniorNotesMember2025-12-310001743881bbio:A2033ConvertibleSeniorNotesMember2026-06-300001743881bbio:A2033ConvertibleSeniorNotesMember2025-12-310001743881us-gaap:RelatedPartyMember2026-06-300001743881us-gaap:RelatedPartyMember2025-12-310001743881us-gaap:ProductMember2026-04-012026-06-300001743881us-gaap:ProductMember2025-04-012025-06-300001743881us-gaap:ProductMember2026-01-012026-06-300001743881us-gaap:ProductMember2025-01-012025-06-300001743881us-gaap:LicenseAndServiceMember2026-04-012026-06-300001743881us-gaap:LicenseAndServiceMember2025-04-012025-06-300001743881us-gaap:LicenseAndServiceMember2026-01-012026-06-300001743881us-gaap:LicenseAndServiceMember2025-01-012025-06-300001743881us-gaap:RoyaltyMember2026-04-012026-06-300001743881us-gaap:RoyaltyMember2025-04-012025-06-300001743881us-gaap:RoyaltyMember2026-01-012026-06-300001743881us-gaap:RoyaltyMember2025-01-012025-06-3000017438812026-04-012026-06-3000017438812025-04-012025-06-3000017438812025-01-012025-06-300001743881bbio:LicenseServicesAndRoyaltyMember2026-04-012026-06-300001743881bbio:LicenseServicesAndRoyaltyMember2025-04-012025-06-300001743881bbio:LicenseServicesAndRoyaltyMember2026-01-012026-06-300001743881bbio:LicenseServicesAndRoyaltyMember2025-01-012025-06-300001743881us-gaap:RelatedPartyMember2026-04-012026-06-300001743881us-gaap:RelatedPartyMember2026-01-012026-06-300001743881us-gaap:CommonStockMember2025-12-310001743881us-gaap:TreasuryStockCommonMember2025-12-310001743881us-gaap:AdditionalPaidInCapitalMember2025-12-310001743881us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001743881us-gaap:RetainedEarningsMember2025-12-310001743881us-gaap:ParentMember2025-12-310001743881us-gaap:NoncontrollingInterestMember2025-12-310001743881us-gaap:CommonStockMember2026-01-012026-03-310001743881us-gaap:TreasuryStockCommonMember2026-01-012026-03-310001743881us-gaap:ParentMember2026-01-012026-03-3100017438812026-01-012026-03-310001743881us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001743881us-gaap:NoncontrollingInterestMember2026-01-012026-03-310001743881us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001743881us-gaap:RetainedEarningsMember2026-01-012026-03-3100017438812026-03-310001743881us-gaap:CommonStockMember2026-03-310001743881us-gaap:TreasuryStockCommonMember2026-03-310001743881us-gaap:AdditionalPaidInCapitalMember2026-03-310001743881us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001743881us-gaap:RetainedEarningsMember2026-03-310001743881us-gaap:ParentMember2026-03-310001743881us-gaap:NoncontrollingInterestMember2026-03-310001743881us-gaap:CommonStockMember2026-04-012026-06-300001743881us-gaap:TreasuryStockCommonMember2026-04-012026-06-300001743881us-gaap:ParentMember2026-04-012026-06-300001743881us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-300001743881us-gaap:NoncontrollingInterestMember2026-04-012026-06-300001743881us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-012026-06-300001743881us-gaap:RetainedEarningsMember2026-04-012026-06-300001743881us-gaap:CommonStockMember2026-06-300001743881us-gaap:TreasuryStockCommonMember2026-06-300001743881us-gaap:AdditionalPaidInCapitalMember2026-06-300001743881us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-300001743881us-gaap:RetainedEarningsMember2026-06-300001743881us-gaap:ParentMember2026-06-300001743881us-gaap:NoncontrollingInterestMember2026-06-3000017438812024-12-310001743881us-gaap:CommonStockMember2024-12-310001743881us-gaap:TreasuryStockCommonMember2024-12-310001743881us-gaap:AdditionalPaidInCapitalMember2024-12-310001743881us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001743881us-gaap:RetainedEarningsMember2024-12-310001743881us-gaap:ParentMember2024-12-310001743881us-gaap:NoncontrollingInterestMember2024-12-310001743881us-gaap:CommonStockMember2025-01-012025-03-310001743881us-gaap:TreasuryStockCommonMember2025-01-012025-03-310001743881us-gaap:ParentMember2025-01-012025-03-3100017438812025-01-012025-03-310001743881us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001743881us-gaap:NoncontrollingInterestMember2025-01-012025-03-310001743881us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001743881us-gaap:RetainedEarningsMember2025-01-012025-03-3100017438812025-03-310001743881us-gaap:CommonStockMember2025-03-310001743881us-gaap:TreasuryStockCommonMember2025-03-310001743881us-gaap:AdditionalPaidInCapitalMember2025-03-310001743881us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001743881us-gaap:RetainedEarningsMember2025-03-310001743881us-gaap:ParentMember2025-03-310001743881us-gaap:NoncontrollingInterestMember2025-03-310001743881us-gaap:CommonStockMember2025-04-012025-06-300001743881us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001743881us-gaap:ParentMember2025-04-012025-06-300001743881us-gaap:NoncontrollingInterestMember2025-04-012025-06-300001743881us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300001743881us-gaap:RetainedEarningsMember2025-04-012025-06-3000017438812025-06-300001743881us-gaap:CommonStockMember2025-06-300001743881us-gaap:TreasuryStockCommonMember2025-06-300001743881us-gaap:AdditionalPaidInCapitalMember2025-06-300001743881us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001743881us-gaap:RetainedEarningsMember2025-06-300001743881us-gaap:ParentMember2025-06-300001743881us-gaap:NoncontrollingInterestMember2025-06-300001743881bbio:A2033ConvertibleSeniorNotesMember2026-01-012026-06-300001743881bbio:A2033ConvertibleSeniorNotesMember2025-01-012025-06-300001743881bbio:A2031ConvertibleSeniorNotesMember2026-01-012026-06-300001743881bbio:A2031ConvertibleSeniorNotesMember2025-01-012025-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:BayerMemberus-gaap:SalesRevenueNetMember2025-01-012025-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:AlexionMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:AlexionMemberus-gaap:SalesRevenueNetMember2025-01-012025-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerAMemberus-gaap:SalesRevenueNetMember2026-04-012026-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerAMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerAMemberus-gaap:SalesRevenueNetMember2026-01-012026-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerAMemberus-gaap:SalesRevenueNetMember2025-01-012025-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerBMemberus-gaap:SalesRevenueNetMember2026-04-012026-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerBMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerBMemberus-gaap:SalesRevenueNetMember2026-01-012026-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerBMemberus-gaap:SalesRevenueNetMember2025-01-012025-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerCMemberus-gaap:SalesRevenueNetMember2026-04-012026-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerCMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerCMemberus-gaap:SalesRevenueNetMember2026-01-012026-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerDMemberus-gaap:SalesRevenueNetMember2026-04-012026-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerDMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerDMemberus-gaap:SalesRevenueNetMember2026-01-012026-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerDMemberus-gaap:SalesRevenueNetMember2025-01-012025-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerEMemberus-gaap:SalesRevenueNetMember2026-04-012026-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerEMemberus-gaap:SalesRevenueNetMember2026-01-012026-06-300001743881us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2026-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerAMemberus-gaap:AccountsReceivableMember2026-01-012026-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerBMemberus-gaap:AccountsReceivableMember2026-01-012026-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerCMemberus-gaap:AccountsReceivableMember2026-01-012026-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerDMemberus-gaap:AccountsReceivableMember2026-01-012026-06-300001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerEMemberus-gaap:AccountsReceivableMember2026-01-012026-06-300001743881us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-12-310001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerAMemberus-gaap:AccountsReceivableMember2025-01-012025-12-310001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerBMemberus-gaap:AccountsReceivableMember2025-01-012025-12-310001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerCMemberus-gaap:AccountsReceivableMember2025-01-012025-12-310001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerDMemberus-gaap:AccountsReceivableMember2025-01-012025-12-310001743881us-gaap:CustomerConcentrationRiskMemberbbio:CustomerEMemberus-gaap:AccountsReceivableMember2025-01-012025-12-310001743881us-gaap:ProductMemberbbio:ReportableSegmentMember2026-04-012026-06-300001743881us-gaap:ProductMemberbbio:ReportableSegmentMember2025-04-012025-06-300001743881us-gaap:ProductMemberbbio:ReportableSegmentMember2026-01-012026-06-300001743881us-gaap:ProductMemberbbio:ReportableSegmentMember2025-01-012025-06-300001743881us-gaap:LicenseAndServiceMemberbbio:ReportableSegmentMember2026-04-012026-06-300001743881us-gaap:LicenseAndServiceMemberbbio:ReportableSegmentMember2025-04-012025-06-300001743881us-gaap:LicenseAndServiceMemberbbio:ReportableSegmentMember2026-01-012026-06-300001743881us-gaap:LicenseAndServiceMemberbbio:ReportableSegmentMember2025-01-012025-06-300001743881us-gaap:RoyaltyMemberbbio:ReportableSegmentMember2026-04-012026-06-300001743881us-gaap:RoyaltyMemberbbio:ReportableSegmentMember2025-04-012025-06-300001743881us-gaap:RoyaltyMemberbbio:ReportableSegmentMember2026-01-012026-06-300001743881us-gaap:RoyaltyMemberbbio:ReportableSegmentMember2025-01-012025-06-300001743881bbio:ReportableSegmentMember2026-04-012026-06-300001743881bbio:ReportableSegmentMember2025-04-012025-06-300001743881bbio:ReportableSegmentMember2026-01-012026-06-300001743881bbio:ReportableSegmentMember2025-01-012025-06-300001743881bbio:LicenseServicesAndRoyaltyMemberbbio:ReportableSegmentMember2026-04-012026-06-300001743881bbio:LicenseServicesAndRoyaltyMemberbbio:ReportableSegmentMember2025-04-012025-06-300001743881bbio:LicenseServicesAndRoyaltyMemberbbio:ReportableSegmentMember2026-01-012026-06-300001743881bbio:LicenseServicesAndRoyaltyMemberbbio:ReportableSegmentMember2025-01-012025-06-300001743881bbio:AcoramidisForTheTreatmentOfATTRCMAndPrimaryPreventionInAsymptomaticCarriersOfAPathogenicTTRVariantMemberbbio:ReportableSegmentMember2026-04-012026-06-300001743881bbio:AcoramidisForTheTreatmentOfATTRCMAndPrimaryPreventionInAsymptomaticCarriersOfAPathogenicTTRVariantMemberbbio:ReportableSegmentMember2025-04-012025-06-300001743881bbio:AcoramidisForTheTreatmentOfATTRCMAndPrimaryPreventionInAsymptomaticCarriersOfAPathogenicTTRVariantMemberbbio:ReportableSegmentMember2026-01-012026-06-300001743881bbio:AcoramidisForTheTreatmentOfATTRCMAndPrimaryPreventionInAsymptomaticCarriersOfAPathogenicTTRVariantMemberbbio:ReportableSegmentMember2025-01-012025-06-300001743881bbio:InfigratinibForAchondroplasiaAndHypochondroplasiaMemberbbio:ReportableSegmentMember2026-04-012026-06-300001743881bbio:InfigratinibForAchondroplasiaAndHypochondroplasiaMemberbbio:ReportableSegmentMember2025-04-012025-06-300001743881bbio:InfigratinibForAchondroplasiaAndHypochondroplasiaMemberbbio:ReportableSegmentMember2026-01-012026-06-300001743881bbio:InfigratinibForAchondroplasiaAndHypochondroplasiaMemberbbio:ReportableSegmentMember2025-01-012025-06-300001743881bbio:BBP418ForLGMD2IR9Memberbbio:ReportableSegmentMember2026-04-012026-06-300001743881bbio:BBP418ForLGMD2IR9Memberbbio:ReportableSegmentMember2025-04-012025-06-300001743881bbio:BBP418ForLGMD2IR9Memberbbio:ReportableSegmentMember2026-01-012026-06-300001743881bbio:BBP418ForLGMD2IR9Memberbbio:ReportableSegmentMember2025-01-012025-06-300001743881bbio:EncaleretForADH1Memberbbio:ReportableSegmentMember2026-04-012026-06-300001743881bbio:EncaleretForADH1Memberbbio:ReportableSegmentMember2025-04-012025-06-300001743881bbio:EncaleretForADH1Memberbbio:ReportableSegmentMember2026-01-012026-06-300001743881bbio:EncaleretForADH1Memberbbio:ReportableSegmentMember2025-01-012025-06-300001743881bbio:OtherDevelopmentProgramsMemberbbio:ReportableSegmentMember2026-04-012026-06-300001743881bbio:OtherDevelopmentProgramsMemberbbio:ReportableSegmentMember2025-04-012025-06-300001743881bbio:OtherDevelopmentProgramsMemberbbio:ReportableSegmentMember2026-01-012026-06-300001743881bbio:OtherDevelopmentProgramsMemberbbio:ReportableSegmentMember2025-01-012025-06-300001743881bbio:OtherResearchProgramsMemberbbio:ReportableSegmentMember2026-04-012026-06-300001743881bbio:OtherResearchProgramsMemberbbio:ReportableSegmentMember2025-04-012025-06-300001743881bbio:OtherResearchProgramsMemberbbio:ReportableSegmentMember2026-01-012026-06-300001743881bbio:OtherResearchProgramsMemberbbio:ReportableSegmentMember2025-01-012025-06-300001743881bbio:ReportableSegmentMemberus-gaap:RelatedPartyMember2026-04-012026-06-300001743881bbio:ReportableSegmentMemberus-gaap:RelatedPartyMember2026-01-012026-06-300001743881country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2026-04-012026-06-300001743881country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001743881country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2026-01-012026-06-300001743881country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-06-300001743881us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2026-04-012026-06-300001743881us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001743881us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2026-01-012026-06-300001743881us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-06-300001743881srt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2026-04-012026-06-300001743881srt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001743881srt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2026-01-012026-06-300001743881srt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-06-300001743881us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2026-04-012026-06-300001743881us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001743881us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2026-01-012026-06-300001743881us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-06-300001743881country:US2026-06-300001743881country:CA2026-06-300001743881bbio:RestOfWorldMember2026-06-300001743881country:US2025-12-310001743881country:CA2025-12-310001743881bbio:RestOfWorldMember2025-12-310001743881us-gaap:MoneyMarketFundsMember2026-06-300001743881us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2026-06-300001743881us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2026-06-300001743881us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2026-06-300001743881us-gaap:USTreasuryBillSecuritiesMember2026-06-300001743881us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-06-300001743881us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-06-300001743881us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel3Member2026-06-300001743881bbio:AgencyDiscountNotesMember2026-06-300001743881bbio:AgencyDiscountNotesMemberus-gaap:FairValueInputsLevel1Member2026-06-300001743881bbio:AgencyDiscountNotesMemberus-gaap:FairValueInputsLevel2Member2026-06-300001743881bbio:AgencyDiscountNotesMemberus-gaap:FairValueInputsLevel3Member2026-06-300001743881us-gaap:FairValueInputsLevel1Member2026-06-300001743881us-gaap:FairValueInputsLevel2Member2026-06-300001743881us-gaap:FairValueInputsLevel3Member2026-06-300001743881us-gaap:USTreasuryBillSecuritiesMember2026-06-300001743881us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-06-300001743881us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-06-300001743881us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel3Member2026-06-300001743881us-gaap:MoneyMarketFundsMember2025-12-310001743881us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2025-12-310001743881us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2025-12-310001743881us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2025-12-310001743881us-gaap:USTreasuryBillSecuritiesMember2025-12-310001743881us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001743881us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001743881us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001743881bbio:AgencyDiscountNotesMember2025-12-310001743881bbio:AgencyDiscountNotesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001743881bbio:AgencyDiscountNotesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001743881bbio:AgencyDiscountNotesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001743881us-gaap:FairValueInputsLevel1Member2025-12-310001743881us-gaap:FairValueInputsLevel2Member2025-12-310001743881us-gaap:FairValueInputsLevel3Member2025-12-310001743881us-gaap:USTreasuryBillSecuritiesMember2025-12-310001743881us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001743881us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001743881us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001743881us-gaap:ConvertibleDebtMemberbbio:A2027ConvertibleSeniorNotesMember2026-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2029ConvertibleSeniorNotesMember2026-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2031ConvertibleSeniorNotesMember2026-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2033ConvertibleSeniorNotesMember2026-06-300001743881bbio:AmendedLoanAgreementMember2026-06-300001743881bbio:AmendedLoanAgreementMember2025-12-310001743881bbio:AgencyDiscountNotesMember2026-06-300001743881bbio:AgencyDiscountNotesMember2025-12-310001743881bbio:GondolaBioLlcMember2024-08-310001743881bbio:GondolaBioLlcMember2026-06-300001743881bbio:GondolaBioLlcMember2026-04-012026-06-300001743881bbio:GondolaBioLlcMember2026-01-012026-06-300001743881bbio:GondolaBioLlcMember2025-04-012025-06-300001743881bbio:GondolaBioLlcMember2025-01-012025-06-300001743881bbio:GondolaBioLlcMember2025-12-310001743881bbio:TransitionServiceAgreementAndSubleaseAgreementMemberbbio:GondolaBioLlcMember2026-04-012026-06-300001743881bbio:TransitionServiceAgreementAndSubleaseAgreementMemberbbio:GondolaBioLlcMember2026-01-012026-06-300001743881bbio:TransitionServiceAgreementAndSubleaseAgreementMemberbbio:GondolaBioLimitedLiabiltyCompanyMember2026-04-012026-06-300001743881bbio:TransitionServiceAgreementAndSubleaseAgreementMemberbbio:GondolaBioLimitedLiabiltyCompanyMember2026-01-012026-06-300001743881bbio:TransitionServiceAgreementAndSubleaseAgreementMemberbbio:GondolaBioLlcMember2025-04-012025-06-300001743881bbio:TransitionServiceAgreementAndSubleaseAgreementMemberbbio:GondolaBioLlcMember2025-01-012025-06-300001743881bbio:TransitionServiceAgreementAndSubleaseAgreementMemberbbio:GondolaBioLimitedLiabiltyCompanyMember2025-04-012025-06-300001743881bbio:TransitionServiceAgreementAndSubleaseAgreementMemberbbio:GondolaBioLimitedLiabiltyCompanyMember2025-01-012025-06-300001743881bbio:TransitionServiceAgreementAndSubleaseAgreementMemberbbio:GondolaBioLimitedLiabiltyCompanyMember2026-06-300001743881bbio:TransitionServiceAgreementAndSubleaseAgreementMemberbbio:GondolaBioLimitedLiabiltyCompanyMember2025-12-310001743881bbio:TransitionServiceAggrementMemberbbio:GondolaBioLimitedLiabiltyCompanyMember2026-04-012026-06-300001743881bbio:TransitionServiceAggrementMemberbbio:GondolaBioLimitedLiabiltyCompanyMember2026-01-012026-06-300001743881bbio:TransitionServiceAggrementMemberbbio:GondolaBioLimitedLiabiltyCompanyMember2025-04-012025-06-300001743881bbio:TransitionServiceAggrementMemberbbio:GondolaBioLimitedLiabiltyCompanyMember2025-01-012025-06-300001743881bbio:BridgeBioOncologyTherapeuticsInc.Member2024-04-302024-04-300001743881bbio:BridgeBioOncologyTherapeuticsInc.Member2026-06-300001743881bbio:BridgeBioOncologyTherapeuticsInc.Member2026-04-012026-06-300001743881bbio:BridgeBioOncologyTherapeuticsInc.Member2026-01-012026-06-300001743881bbio:BridgeBioOncologyTherapeuticsInc.Member2025-04-012025-06-300001743881bbio:BridgeBioOncologyTherapeuticsInc.Member2025-01-012025-06-300001743881bbio:BridgeBioOncologyTherapeuticsInc.Member2025-12-310001743881us-gaap:FairValueInputsLevel1Memberbbio:BridgeBioOncologyTherapeuticsInc.Member2026-06-300001743881us-gaap:FairValueInputsLevel1Memberbbio:BridgeBioOncologyTherapeuticsInc.Member2025-12-310001743881us-gaap:ConvertibleDebtMemberbbio:A2027ConvertibleSeniorNotesMember2020-03-090001743881us-gaap:ConvertibleDebtMemberbbio:A2027NotesInitialPurchasersMember2020-03-090001743881us-gaap:ConvertibleDebtMemberbbio:A2027ConvertibleSeniorNotesMember2020-03-092020-03-090001743881bbio:DebtConversionTermsOneMemberus-gaap:ConvertibleDebtMemberbbio:A2027ConvertibleSeniorNotesMember2020-03-092020-03-090001743881bbio:DebtConversionTermsTwoMemberus-gaap:ConvertibleDebtMemberbbio:A2027ConvertibleSeniorNotesMember2020-03-092020-03-090001743881us-gaap:ConvertibleDebtMemberbbio:A2029ConvertibleSeniorNotesMember2021-01-280001743881us-gaap:ConvertibleDebtMemberbbio:A2029NotesInitialPurchasersMember2021-01-280001743881us-gaap:ConvertibleDebtMemberbbio:A2029ConvertibleSeniorNotesMember2021-02-020001743881us-gaap:ConvertibleDebtMemberbbio:A2029ConvertibleSeniorNotesMember2021-01-282021-01-280001743881bbio:DebtConversionTermsOneMemberus-gaap:ConvertibleDebtMemberbbio:A2029ConvertibleSeniorNotesMember2021-01-282021-01-280001743881bbio:DebtConversionTermsTwoMemberus-gaap:ConvertibleDebtMemberbbio:A2029ConvertibleSeniorNotesMember2021-01-282021-01-280001743881us-gaap:ConvertibleDebtMemberbbio:A2031ConvertibleSeniorNotesMember2025-02-280001743881us-gaap:ConvertibleDebtMemberbbio:A2031NotesInitialPurchasersMember2025-02-280001743881us-gaap:SeniorNotesMemberbbio:A2025NoteOfferingMember2025-02-282025-02-280001743881bbio:DebtConversionTermsOneMemberus-gaap:ConvertibleDebtMemberbbio:A2031ConvertibleSeniorNotesMember2025-02-282025-02-280001743881bbio:DebtConversionTermsTwoMemberus-gaap:ConvertibleDebtMemberbbio:A2031ConvertibleSeniorNotesMember2025-02-282025-02-280001743881us-gaap:ConvertibleDebtMemberbbio:A2031ConvertibleSeniorNotesMember2025-02-282025-02-280001743881us-gaap:ConvertibleDebtMemberbbio:A2033ConvertibleSeniorNotesMember2026-01-210001743881us-gaap:ConvertibleDebtMemberbbio:A2033NotesInitialPurchasersMember2026-01-210001743881us-gaap:ConvertibleDebtMemberbbio:A2033ConvertibleSeniorNotesMember2026-01-212026-01-210001743881bbio:DebtConversionTermsOneMemberus-gaap:ConvertibleDebtMemberbbio:A2033ConvertibleSeniorNotesMember2026-01-212026-01-210001743881bbio:DebtConversionTermsTwoMemberus-gaap:ConvertibleDebtMemberbbio:A2033ConvertibleSeniorNotesMember2026-01-212026-01-210001743881us-gaap:ConvertibleDebtMemberbbio:A2027ConvertibleSeniorNotesMember2025-12-310001743881us-gaap:ConvertibleDebtMemberbbio:A2029ConvertibleSeniorNotesMember2025-12-310001743881us-gaap:ConvertibleDebtMemberbbio:A2031ConvertibleSeniorNotesMember2025-12-310001743881us-gaap:ConvertibleDebtMemberbbio:A2027ConvertibleSeniorNotesMember2026-04-012026-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2029ConvertibleSeniorNotesMember2026-04-012026-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2031ConvertibleSeniorNotesMember2026-04-012026-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2033ConvertibleSeniorNotesMember2026-04-012026-06-300001743881us-gaap:ConvertibleDebtMember2026-04-012026-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2027ConvertibleSeniorNotesMember2025-04-012025-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2029ConvertibleSeniorNotesMember2025-04-012025-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2031ConvertibleSeniorNotesMember2025-04-012025-06-300001743881us-gaap:ConvertibleDebtMember2025-04-012025-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2027ConvertibleSeniorNotesMember2025-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2029ConvertibleSeniorNotesMember2025-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2031ConvertibleSeniorNotesMember2025-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2027ConvertibleSeniorNotesMember2026-01-012026-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2029ConvertibleSeniorNotesMember2026-01-012026-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2031ConvertibleSeniorNotesMember2026-01-012026-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2033ConvertibleSeniorNotesMember2026-01-012026-06-300001743881us-gaap:ConvertibleDebtMember2026-01-012026-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2027ConvertibleSeniorNotesMember2025-01-012025-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2029ConvertibleSeniorNotesMember2025-01-012025-06-300001743881us-gaap:ConvertibleDebtMemberbbio:A2031ConvertibleSeniorNotesMember2025-01-012025-06-300001743881us-gaap:ConvertibleDebtMember2025-01-012025-06-300001743881bbio:A2021CappedCallTransactionsMember2021-01-252021-01-250001743881bbio:A2020CappedCallTransactionsMember2020-03-042020-03-040001743881bbio:A2021CappedCallTransactionsMember2021-01-250001743881bbio:A2020CappedCallTransactionsMember2020-03-040001743881bbio:A2021CappedCallTransactionsMember2020-03-042020-03-040001743881bbio:A2021And2020CappedCallTransactionsMember2020-03-042021-01-250001743881bbio:A2020NoteOfferingMember2020-03-042020-03-040001743881bbio:A2020NoteOfferingMember2020-03-040001743881bbio:A2021NoteOfferingMember2021-01-252021-01-250001743881bbio:A2021NoteOfferingMember2021-01-250001743881bbio:A2025NoteOfferingMember2025-02-252025-02-250001743881bbio:A2025NoteOfferingMember2025-02-250001743881bbio:A2026NoteOfferingMember2026-01-152026-01-150001743881bbio:A2026NoteOfferingMember2026-01-150001743881bbio:FinancingAgreementMember2024-01-310001743881us-gaap:SecuredDebtMemberbbio:InitialTermLoanMember2024-01-310001743881us-gaap:SecuredDebtMemberbbio:IncrementalTermLoanMember2024-01-310001743881us-gaap:SecuredDebtMemberbbio:InitialTermLoanMember2024-01-012024-01-310001743881us-gaap:SecuredDebtMemberbbio:FinancingAgreementMember2025-02-282025-02-280001743881bbio:FinancingAgreementMember2025-01-012025-02-280001743881bbio:RoyaltyInterestPurchaseAndSaleAgreementMemberbbio:EidosTherapeuticsInc.Member2023-06-302023-06-300001743881bbio:RoyaltyInterestPurchaseAndSaleAgreementMember2023-06-302023-06-300001743881bbio:RoyaltyInterestPurchaseAndSaleAgreementMember2025-06-012025-06-300001743881bbio:FundingAgreementMember2024-01-172024-01-170001743881bbio:FundingAgreementMember2024-12-012024-12-310001743881bbio:FundingAgreementMember2026-06-300001743881bbio:FundingAgreementMember2025-12-310001743881bbio:RoyaltyPurchaseAgreementMember2026-06-300001743881bbio:RoyaltyPurchaseAgreementMemberus-gaap:RelatedPartyMember2026-06-300001743881bbio:RoyaltyPurchaseAgreementMember2025-12-310001743881bbio:RoyaltyPurchaseAgreementMemberus-gaap:RelatedPartyMember2025-12-310001743881bbio:FundingAgreementMember2026-04-012026-06-300001743881bbio:FundingAgreementMember2026-01-012026-06-300001743881bbio:FundingAgreementMember2025-04-012025-06-300001743881bbio:FundingAgreementMember2025-01-012025-06-300001743881bbio:RoyaltyPurchaseAgreementMember2026-04-012026-06-300001743881bbio:RoyaltyPurchaseAgreementMember2026-01-012026-06-300001743881bbio:RoyaltyPurchaseAgreementMember2025-06-272025-06-300001743881us-gaap:LicenseAndServiceMemberbbio:SellerPartiesMemberbbio:BayerMember2024-03-010001743881bbio:SellerPartiesMemberbbio:BayerMember2024-03-010001743881bbio:SellerPartiesMemberbbio:BayerMember2024-03-012024-03-010001743881us-gaap:LicenseAndServiceMemberbbio:SellerPartiesMemberbbio:BayerMember2024-03-012024-03-010001743881bbio:BayerMemberus-gaap:LicenseAndServiceMember2024-03-012024-03-010001743881bbio:BayerMember2024-03-310001743881bbio:BayerMemberus-gaap:LicenseAndServiceMember2025-01-012025-06-300001743881bbio:BayerMemberus-gaap:LicenseMember2024-03-310001743881bbio:BayerMemberbbio:ResearchAndDevelopmentServicesMember2024-03-310001743881bbio:BayerMember2026-01-012026-06-300001743881bbio:BayerMemberus-gaap:LicenseAndServiceMember2026-04-012026-06-300001743881bbio:BayerMemberus-gaap:LicenseAndServiceMember2026-01-012026-06-300001743881bbio:BayerMemberus-gaap:LicenseAndServiceMember2025-04-012025-06-300001743881bbio:BayerMember2026-06-300001743881bbio:BayerMember2025-12-310001743881bbio:BayerMemberbbio:LicenseServicesAndRoyaltyMember2026-04-012026-06-300001743881bbio:BayerMemberbbio:LicenseServicesAndRoyaltyMember2026-01-012026-06-300001743881bbio:BayerMemberbbio:ResearchAndDevelopmentServicesMember2026-06-300001743881bbio:BayerMemberbbio:ResearchAndDevelopmentServicesMember2025-12-310001743881bbio:QEDTherapeuticsInc.Memberbbio:KyowaKirinCo.LtdMember2024-02-290001743881bbio:KyowaKirinCo.LtdMember2024-02-012024-02-290001743881bbio:KyowaKirinCo.LtdMember2024-02-290001743881bbio:KyowaKirinCo.LtdMemberus-gaap:LicenseMember2024-02-290001743881bbio:KyowaKirinCo.LtdMemberbbio:ResearchAndDevelopmentServicesMember2024-02-290001743881bbio:KyowaKirinCo.LtdMember2026-01-012026-06-300001743881bbio:KyowaKirinCo.LtdMemberus-gaap:LicenseAndServiceMember2026-04-012026-06-300001743881bbio:KyowaKirinCo.LtdMemberus-gaap:LicenseAndServiceMember2026-01-012026-06-300001743881bbio:KyowaKirinCo.LtdMemberus-gaap:LicenseAndServiceMember2025-04-012025-06-300001743881bbio:KyowaKirinCo.LtdMemberus-gaap:LicenseAndServiceMember2025-01-012025-06-300001743881bbio:KyowaKirinCo.LtdMember2026-06-300001743881bbio:KyowaKirinCo.LtdMember2025-12-310001743881bbio:EidosTherapeuticsInc.Memberbbio:AlexionLicenseAgreementsMember2019-09-300001743881us-gaap:LicenseAndServiceMemberbbio:EidosTherapeuticsInc.Memberbbio:AlexionLicenseAgreementsMember2019-09-012019-09-300001743881bbio:AlexionLicenseAgreementsMemberus-gaap:LicenseAndServiceMember2026-04-012026-06-300001743881bbio:AlexionLicenseAgreementsMemberus-gaap:LicenseAndServiceMember2026-01-012026-06-300001743881bbio:AlexionLicenseAgreementsMemberus-gaap:LicenseAndServiceMember2025-04-012025-06-300001743881bbio:AlexionLicenseAgreementsMemberus-gaap:LicenseAndServiceMember2025-01-012025-06-300001743881bbio:QEDTherapeuticsInc.Memberbbio:KyowaKirinCo.LtdMember2024-02-070001743881bbio:EidosTherapeuticsInc.Memberbbio:StanfordLicenseAgreementMember2016-04-300001743881bbio:EidosTherapeuticsInc.Memberbbio:StanfordLicenseAgreementMember2026-01-012026-06-300001743881bbio:EidosTherapeuticsInc.Memberbbio:StanfordLicenseAgreementMember2026-04-012026-06-300001743881bbio:EidosTherapeuticsInc.Memberbbio:StanfordLicenseAgreementMember2025-04-012025-06-300001743881bbio:EidosTherapeuticsInc.Memberbbio:StanfordLicenseAgreementMember2025-01-012025-06-300001743881bbio:TwoThousandTwentyThreeShelfRegistrationStatementAndATMAgreementMember2023-05-310001743881bbio:TwoThousandTwentyThreeShelfRegistrationStatementAndATMAgreementMember2023-05-012023-05-310001743881bbio:TwoThousandTwentyThreeShelfRegistrationStatementAndATMAgreementMember2023-05-012026-05-070001743881bbio:TwoThousandTwentySixShelfRegistrationStatementAndATMAgreementMember2026-05-310001743881bbio:TwoThousandTwentySixShelfRegistrationStatementAndATMAgreementMember2026-05-012026-05-310001743881bbio:TwoThousandTwentySixShelfRegistrationStatementAndATMAgreementMember2026-06-300001743881bbio:TwoThousandTwentySixShareRepurchaseProgramMemberus-gaap:CommonStockMember2026-05-310001743881bbio:TwoThousandTwentySixShareRepurchaseProgramMember2026-01-012026-06-300001743881us-gaap:CostOfRevenue2026-04-012026-06-300001743881us-gaap:CostOfRevenue2025-04-012025-06-300001743881us-gaap:CostOfRevenue2026-01-012026-06-300001743881us-gaap:CostOfRevenue2025-01-012025-06-300001743881us-gaap:ResearchAndDevelopmentExpense2026-04-012026-06-300001743881us-gaap:ResearchAndDevelopmentExpense2025-04-012025-06-300001743881us-gaap:ResearchAndDevelopmentExpense2026-01-012026-06-300001743881us-gaap:ResearchAndDevelopmentExpense2025-01-012025-06-300001743881us-gaap:SellingGeneralAndAdministrativeExpense2026-04-012026-06-300001743881us-gaap:SellingGeneralAndAdministrativeExpense2025-04-012025-06-300001743881us-gaap:SellingGeneralAndAdministrativeExpense2026-01-012026-06-300001743881us-gaap:SellingGeneralAndAdministrativeExpense2025-01-012025-06-300001743881us-gaap:RestructuringSettlementAndImpairmentProvisions2026-04-012026-06-300001743881us-gaap:RestructuringSettlementAndImpairmentProvisions2025-04-012025-06-300001743881us-gaap:RestructuringSettlementAndImpairmentProvisions2026-01-012026-06-300001743881us-gaap:RestructuringSettlementAndImpairmentProvisions2025-01-012025-06-300001743881bbio:UnvestedRestrictedStockUnitMember2026-01-012026-06-300001743881bbio:UnvestedRestrictedStockUnitMember2025-01-012025-06-300001743881bbio:UnvestedPerformanceBasedRestrictedStockUnitMember2026-01-012026-06-300001743881bbio:UnvestedPerformanceBasedRestrictedStockUnitMember2025-01-012025-06-300001743881bbio:UnvestedMarketBasedRestrictedStockUnitMember2026-01-012026-06-300001743881bbio:UnvestedMarketBasedRestrictedStockUnitMember2025-01-012025-06-300001743881bbio:CommonStockOptionsIssuedAndOutstandingMember2026-01-012026-06-300001743881bbio:CommonStockOptionsIssuedAndOutstandingMember2025-01-012025-06-300001743881bbio:EstimatedSharesIssuablePerformanceBasedMilestoneCompensationArrangementMember2026-01-012026-06-300001743881bbio:EstimatedSharesIssuablePerformanceBasedMilestoneCompensationArrangementMember2025-01-012025-06-300001743881bbio:EstimatedSharesIssuableEmployeeStockPurchasePlanMember2026-01-012026-06-300001743881bbio:EstimatedSharesIssuableEmployeeStockPurchasePlanMember2025-01-012025-06-300001743881bbio:AssumedConversionOfTwoThousandTwentySevenNotesMember2026-01-012026-06-300001743881bbio:AssumedConversionOfTwoThousandTwentySevenNotesMember2025-01-012025-06-300001743881bbio:AssumedConversionOfTwoThousandTwentyNineNotesMember2026-01-012026-06-300001743881bbio:AssumedConversionOfTwoThousandTwentyNineNotesMember2025-01-012025-06-300001743881bbio:AssumedConversionOfTwoThousandThirtyOneNotesMember2026-01-012026-06-300001743881bbio:AssumedConversionOfTwoThousandThirtyOneNotesMember2025-01-012025-06-300001743881bbio:AssumedConversionOfTwoThousandThirtyThreeNotesMember2026-01-012026-06-300001743881bbio:AssumedConversionOfTwoThousandThirtyThreeNotesMember2025-01-012025-06-300001743881us-gaap:SubsequentEventMemberbbio:SeriesACumulativeConvertibleParticipatingPreferredStockMember2026-07-010001743881us-gaap:SubsequentEventMemberbbio:SeriesACumulativeConvertibleParticipatingPreferredStockMemberbbio:InvestmentAgreementMember2026-07-012026-07-010001743881us-gaap:SubsequentEventMemberbbio:SeriesACumulativeConvertibleParticipatingPreferredStockMemberbbio:InvestmentAgreementMember2026-07-010001743881us-gaap:SubsequentEventMemberbbio:SeriesACumulativeConvertibleParticipatingPreferredStockMemberbbio:InvestmentAgreementMemberbbio:SixthStreetPurchaserMember2026-07-012026-07-010001743881us-gaap:SubsequentEventMemberbbio:SeriesACumulativeConvertibleParticipatingPreferredStockMemberbbio:InvestmentAgreementMemberbbio:HCRPurchaserMember2026-07-012026-07-010001743881us-gaap:SubsequentEventMember2026-07-010001743881us-gaap:SubsequentEventMemberbbio:SeriesACumulativeConvertibleParticipatingPreferredStockMember2026-07-012026-07-010001743881us-gaap:SubsequentEventMemberbbio:SeriesACumulativeConvertibleParticipatingPreferredStockMemberbbio:VariableRateSeventhAnniversaryMember2026-07-012026-07-010001743881us-gaap:SubsequentEventMemberbbio:SeriesACumulativeConvertibleParticipatingPreferredStockMemberbbio:VariableRateEighthAnniversaryAndEndOfEachThirdMonthThereafterMember2026-07-012026-07-010001743881us-gaap:SubsequentEventMemberbbio:SeriesACumulativeConvertibleParticipatingPreferredStockMemberbbio:VariableRateTriggeringEventMember2026-07-012026-07-010001743881us-gaap:SubsequentEventMemberbbio:SeriesACumulativeConvertibleParticipatingPreferredStockMemberbbio:VariableRateChangeOfControlTransactionMember2026-07-012026-07-010001743881us-gaap:SubsequentEventMemberbbio:VariableConversionPriceClosingDateMember2026-07-010001743881us-gaap:SubsequentEventMemberbbio:VariableConversionPriceOnAndAfterFifthAnniversaryMember2026-07-010001743881us-gaap:SubsequentEventMember2026-07-012026-07-010001743881bbio:VariableRedemptionAfterThirdAnniversaryMemberus-gaap:SubsequentEventMember2026-07-012026-07-010001743881bbio:VariableRedemptionAfterFourthAnniversaryMemberus-gaap:SubsequentEventMember2026-07-012026-07-010001743881us-gaap:SubsequentEventMembersrt:MaximumMember2026-07-012026-07-010001743881us-gaap:SubsequentEventMember2026-07-152026-07-150001743881bbio:NeilKumarMember2026-04-012026-06-300001743881bbio:NeilKumarMember2026-06-30

Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________________________________
FORM 10-Q
________________________________________________________
(Mark One)
x              QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2026
or
o              TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                to                
Commission File Number: 001-38959
________________________________________________________
BridgeBio Pharma, Inc. 
(Exact name of registrant as specified in its charter)
________________________________________________________

Delaware84-1850815
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
3160 Porter Drive, Suite 250, Palo Alto, CA
94304
(Address of principal executive offices)(Zip Code)

(650) 391-9740
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading
Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareBBIOThe Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
________________________________________________________

Large accelerated filerxAccelerated filero
Non-accelerated fileroSmaller reporting companyo
Emerging growth companyo

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o   No  x
As of August 3, 2026, the registrant had 195,487,474 shares of common stock, $0.001 par value per share, outstanding.

Table of Contents

Special Note Regarding Forward‑Looking Statements
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Many of these statements can be identified by the use of terminology such as “believes,” “expects,” “intends,” “anticipates,” “plans,” “may,” “will,” “could,” “would,” “projects,” “continues,” “estimates,” “potential,” “opportunity” or the negative versions of these terms and other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q include, but are not limited to, statements regarding:
•the continued commercial success of AttrubyTM (acoramidis), including our expectations regarding the size and growth potential of the commercial markets for Attruby;
•the success, cost and timing of our clinical development of our late-stage product candidates, including low-dose infigratinib for achondroplasia, encaleret for ADH1, and BBP-418 for limb-girdle muscular dystrophy type 2I/R9, or LGMD2I/R9; 
•our ability to continue planned preclinical and clinical development of our respective development programs, and the timing, cost and success of any such continued preclinical and clinical development and planned regulatory submissions;
•our ability to initiate, recruit and enroll patients in and conduct our clinical trials at the pace that we project;
•the expected timing of our regulatory submissions, and our anticipated interaction with and feedback from the U.S. Food and Drug Administration (the “FDA”) and similar regulatory authorities;
•our plans to implement certain development strategies, including our ability to attract and retain potential collaborators with development, regulatory and commercialization expertise;
•our ability to obtain and maintain regulatory approval of our product candidates in any of the indications for which we are developing or we plan to develop, and any related restrictions, limitations or warnings in the label of any of our product candidates, if approved;
•our ability to successfully commercialize our current product candidates, if approved, and any other product candidates we may identify and pursue, if approved, including our ability to successfully build a specialty sales force and commercial infrastructure to market our current product candidates and any other product candidates we may identify and pursue;
•our ability to compete with companies currently marketing approved treatments or engaged in the development of treatments that may become available for any of the indications that our product candidates are designed to target;
•our reliance on third parties to conduct our clinical trials and to manufacture drug substance and drug product for our commercial product and certain of our product candidates for use in our clinical trials;
•our ability to contract with and the performance of our and our collaborators’ third-party suppliers and manufacturers; 
•the pricing and reimbursement of our product candidates, if approved;
•the size and growth potential of the markets for our current product candidates or other product candidates we may identify and pursue, and our ability to serve and gain acceptance by those markets;
•our ability to identify and advance through clinical development any additional product candidates;
•the impacts of public health crises or macroeconomic factors that could impact our business, such as the effects of the ongoing conflicts in the Ukraine or in the Middle East on the global economy; supply chain and inflationary pressures, or significant political, trade or regulatory developments in the jurisdictions in which we may sell our products or conduct our operations;
•our ability to retain and recruit key personnel;
•the success of competing therapies that are or may become available;
•our ability to obtain and maintain adequate intellectual property rights for our product candidates and our ability to operate our business without infringing on the intellectual property rights of others;
•our expectations regarding government and third-party payor coverage and reimbursement;

Table of Contents

•our estimates of our expenses, ongoing losses, capital requirements and our use of cash resources, and our needs for or ability to pay for debt interests and obtain additional financing to complete the clinical trials of any of our product candidates;
•the impact of laws and regulations in the United States and foreign countries;
•our financial performance, including our anticipated funding to support the potential launch of three additional medicines globally;
•adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties; and
•developments and projections relating to our competitors or our industry.
Our actual results or experience could differ significantly from the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in “Risk Factors,” in Part II, Item 1A of this Quarterly Report on Form 10-Q as well as information provided elsewhere in this Quarterly Report on Form 10-Q, our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 24, 2026, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which was filed with the SEC on May 7, 2026. You should carefully consider that information before you make an investment decision.
You should not place undue reliance on these types of forward-looking statements, which speak only as of the date that they were made. These forward-looking statements are based on the beliefs and assumptions of the Company’s management based on information currently available to management and should be considered in connection with any written or oral forward-looking statements that the Company may issue in the future as well as other cautionary statements the Company has made and may make. Except as required by law, the Company does not undertake any obligation to release publicly any revisions to these forward-looking statements after completion of the filing of this Quarterly Report on Form 10-Q to reflect later events or circumstances or the occurrence of unanticipated events.
The discussion of the Company’s financial condition and results of operations should be read in conjunction with the Company’s Condensed Consolidated Financial Statements and the related notes thereto included in this Quarterly Report on Form 10-Q.

Table of Contents

Risk Factors Summary
Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Discussion of the risks listed below, and other risks that we face, are discussed in the section titled “Risk Factors” in Part II, Item 1A of this Quarterly Report on Form 10-Q and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q and our other filings with the SEC before making investment decisions regarding our common stock.
•Our business is substantially dependent on the commercial success of Attruby and Beyonttra. The continued commercial success of this product, along with our product candidates, if approved, will depend upon the degree of market acceptance by physicians, patients, healthcare payors, and others in the medical community.
•If our sales and marketing capabilities for Attruby and Beyonttra, and our future product candidates, if approved, are not effective or we are unable to establish sales and marketing capabilities or enter into and maintain our agreements with third parties to sell and market Attruby and Beyonttra or any future product candidates approved for commercial sale, we may be unsuccessful in our commercial efforts.
•Our profitability will depend significantly on our ability to sell enough product at competitive prices and on the availability of adequate coverage and reimbursement through governmental or private third-party payors. 
•Our future growth may depend, in part, on our ability to penetrate foreign markets, whe